Clinical Trial Update: A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH [Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 2 trial evaluating the efficacy and safety of VK2809 in adults with biopsy-confirmed nonalcoholic steatohepatitis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• VK2809

Snippet

Sponsor: Viking Therapeutics, Inc. | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED